Vicore Pharma Holding AB

FRC's fair value estimate for Vicore Pharma Holding AB, and the rating behind it. VCRE last traded at $9.40; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Vicore Pharma Holding AB. Starting points for Vicore Pharma Holding AB: EPS -$17.83, beta 0.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Vicore Pharma Holding AB. Vicore Pharma Holding AB does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Vicore Pharma Holding AB. Trailing twelve-month EPS for Vicore Pharma Holding AB stands at -$17.83. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Vicore Pharma Holding AB. Vicore Pharma Holding AB has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Vicore Pharma Holding AB valued side by side against its closest peers. Vicore Pharma Holding AB is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Vicore Pharma Holding AB, and how their positions are changing. At a $265.5M market value, institutional positions materially move Vicore Pharma Holding AB's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Vicore Pharma Holding AB executives and directors. Shares of Vicore Pharma Holding AB have traded between $10.50 and $17.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Vicore Pharma Holding AB. Vicore Pharma Holding AB is a $265.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Vicore Pharma Holding AB. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Vicore Pharma Holding AB. Coverage tracks Vicore Pharma Holding AB within Biotechnology (Healthcare). Press releases and market coverage, newest first.